Jan

25

Investment Possibility in Cord Blood Business?

Filed Under Biotechnology & Drugs 

Cord Blood America (Public, OTC: CBAI) is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children.  The company’s mission is to be the most respected stem cell preservation company in the industry.  Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders.

For an initial fee of approx. $1,950 and an annual storage fee of approx. $125 for each year thereafter, the company provides the following services to each customer:

  1. Collection
  2. Full-Time Physician and Customer Support
  3. Transportation
  4. Comprehensive Testing
  5. Cord Blood Preservation

Currently, all of Co.’s cord blood units are tested, processed and stored at Bergen Community Regional Blood Center in Paramus, NJ.

The stem cells are believed to play a key role in fighting disease as we move forward through this century.  Scientists are confident that stem cells will launch a new era in medicine, perhaps even curing some of our most current intractable diseases.  The umbilical cord which, at birth, traditionally has been thrown away, contains a rich store of stem cells.  Cord Blood America, Inc., through its wholly owned subsidiaries, CorCell Companies Inc., and Cord Partners, Inc., markets a service to preserve and store the umbilical cord blood in a patented process for future use exclusively by the donating family.  The collection takes less than five minutes, is painless, easy and non-invasive.  Cryogenically preserved umbilical cord stem cells have already been used to treat 75 major diseases, including leukemia, severe anemia, metabolic blood disorders and immune deficiencies.  This list is guaranteed to grow as medical research learns more about the incredible healing power of stem cells.

You cannot give birth to the same child twice.  That is why marketing, and education, is such an important factor in this sector.  Cord Blood America has assembled an experienced marketing team second to none in the industry.  They have nurtured deep relationships with healthcare insurance providers in key cities to drive the message to the parents when the insurance company is notified of that parent’s pregnancy.

Last month, Cord Blood America did a press release on how umbilical cord blood stem cells are being used in experimental effort to treat type 1 diabetes. Type 1 diabetes occurs when the body’s immune system cells attack the insulin-producing cells in the pancreas. This means the cells don’t produce enough insulin, and the lost insulin has to be replaced through injections for the patient to survive. The scientists involved in the experiment said the treatment could potentially be useful in other autoimmune diseases, such as lupus and rheumatoid arthritis.

A couple of hours later, another press release came out saying that the experiment was successful. said that stem cells from cord blood have been used to reeducate the immune system T cells of people with type 1 diabetes so their pancreas started producing again, lowering the amount of insulin they needed to inject.

The stock has not moved much the past 6 months.  In fact, it was slowly decreasing from $0.14 to $0.04 now.  If you want to invest, might as well do it for a long-term.  Click on the image to view the larger version.

Quote of the Day:
Behind every great fortune, there is a crime. – Honore de Balzac

  • Share/Bookmark

Comments

Leave a Reply